Polatuzumab Vedotin
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
- Polatuzumab Vedotin
- Polatuzumab Vedotin: From Diffuse Large B-Cell Lymphoma to HER2 Positive Breast Carcinoma
Polatuzumab Vedotin: From Diffuse Large B-Cell Lymphoma to HER2 Positive Breast Carcinoma
One-Sentence Summary
Polatuzumab vedotin is an anti-CD79b antibody-drug conjugate (ADC) originally developed for relapsed/refractory Diffuse Large B-Cell Lymphoma (DLBCL). The TxGNN model predicts it may be effective for HER2 positive breast carcinoma, but this prediction is currently supported by 0 clinical trials and 0 publications, and the model’s own rationale flags it as mechanistically implausible.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Diffuse Large B-Cell Lymphoma (DLBCL) — per known drug class (no structured license data on file; drug is not marketed in this jurisdiction) |
| Predicted New Indication | HER2 positive breast carcinoma |
| TxGNN Prediction Score | 99.34% |
| Evidence Level | L5 |
| EU Market Status | ✗ Not marketed (Not marketed) |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, no verified structured mechanism-of-action (MOA) record is available for Polatuzumab vedotin in this evidence pack — this is flagged internally as a High-severity data gap requiring a DrugBank API lookup. Based on the drug-class context noted in the model’s own rationale, Polatuzumab vedotin is an anti-CD79b antibody-drug conjugate (ADC) that delivers the microtubule-disrupting cytotoxic payload MMAE specifically to CD79b-expressing B cells, and it is approved for relapsed/refractory DLBCL in combination regimens.
CD79b is a surface marker restricted to the B-cell lineage; it is not expressed on breast epithelial or breast tumor cells. This means the antibody targeting component of the ADC has no biological mechanism to engage HER2-positive, PR-positive, PR-negative, luminal A/B, or normal breast-like breast tumors — the mechanistic rationale linking the original indication to any of the predicted breast cancer subtypes is weak to absent.
The TxGNN knowledge-graph score for this pairing is high (99.34%), but it is not corroborated by any registered clinical trial or relevant literature. This pattern — a high embedding score with zero real-world evidence and no plausible target biology — is consistent with a knowledge-graph false positive rather than a genuine repurposing signal, as explicitly noted in the evidence pack’s own repurposing rationale.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
EU Market Information
This drug currently holds no EU marketing authorizations (0 licenses on file; market status: Not marketed／not marketed).
Cytotoxicity
| Item | Content |
|---|---|
| Cytotoxicity Classification | Targeted therapy (Antibody-drug conjugate) with cytotoxic microtubule-inhibitor payload (MMAE) |
| Myelosuppression Risk | Medium–High (class effect of MMAE-based ADCs; neutropenia commonly reported — please refer to the SmPC for drug-specific data, as detailed toxicity data is not on file) |
| Emetogenicity Classification | Low to moderate (typical of ADC-class agents; not confirmed for this specific product) |
| Monitoring Items | CBC with differential (neutropenia), liver function tests, peripheral neuropathy assessment (MMAE-related) |
| Handling Protection | Yes — must follow institutional hazardous/cytotoxic drug handling protocols given the MMAE payload |
Safety Considerations
Please refer to the SmPC for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction carries a high TxGNN score but zero corroborating clinical trials or literature (Evidence Level L5), and the mechanistic rationale itself indicates CD79b — the drug’s only known target — is not expressed in breast tumor tissue, making the biological plausibility of this repurposing candidate weak. The same pattern (high score, no evidence, no target expression) also applies to the other 9 predicted indications in this candidate set, several of which (e.g., antithrombin deficiency, heparin cofactor 2 deficiency) appear to be unrelated coagulation disorders with no conceivable mechanistic link, and one (luminal A/B breast cancer) shows literature counts that on inspection are likely a text-mining artifact from the letter “B” rather than genuine relevance.
To proceed, the following is needed:
- Resolve the Blocking-severity data gap (DG001): obtain TFDA/regional label warnings and contraindications before any safety-stage (S1) review
- Resolve the High-severity data gap (DG002): obtain verified MOA data from DrugBank API
- Independent confirmation of CD79b (or any alternative target) expression status in HER2-positive breast carcinoma tissue
- Do not advance beyond S0 unless genuine clinical trial or peer-reviewed evidence emerges for this specific drug-indication pairing
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.